阿斯利康Wainua心脏病试验未降死亡
2026-07-09 07:42:13
据彭博社报道，阿斯利康与Ionis Pharmaceuticals Inc.的基因沉默药物Wainua在一种罕见且可能致命的心脏疾病试验中，未能帮助预防患者心脏问题，也未能降低死亡率。阿斯利康股价下挫。
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
墨奇智能完成超10亿元天使轮融资Next article：
Prologis称Segro数据中心计划依赖过度负债
